| General information |
| Database: | DB01016 |
| Objective: | they wanted to compare the efficacy of the new CT response evaluation criteria for predicting the tumor progression free survival (PFS) with that of RECIST 1.1 in non small cell lung cancer (non small cell lung cancer) patients who were treated with bevacizumab. |
| Authors: | Lee HY, et al |
| Title: | Molecularly targeted therapy using bevacizumab for non small cell lung cancer: a pilot study for the new CT response criteria. |
| Journal: | Korean J Radiol |
| Year: | 2010 |
| PMID: | 21076587 |
| Trial Design |
| Clinical Trial Id: | NA |
| Agent: | bevacizumab
|
| Target: | Vascular endothelial growth factor
|
| Cancer Type: | non small cell lung cancer |
| Cancer Subtype: | non small cell lung cancer |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | CT response criteria |
| Key Patients Feature: | non small cell lung cancer (non small cell lung cancer) patients |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | To evaluate the capabilities of the different measurement methods to predict the patient prognosis, the PFS were compared, using the log rank test, among the responder groups (complete response [CR], partial response [PR], stable disease [SD] and progressive disease [PD]) in terms of the four different methods. |
| Primary End Point: | the capabilities of the different measurement methods to predict the patient prognosis |
| Secondary End Point: | NA |
| Patients Number: | 16 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | The overall (CR, PR or SD) response rates according to RECIST, RECISTsolid, the alternative method and the combined criteria were 81%, 88%, 81% and 85%, respectively. |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | NA |
| Conclusions: | The response outcome evaluations using the three different CT response criteria that reflect tumor cavitation, the groundglass opacity component and the attenuation changes in non small cell lung cancer patients treated with bevacizumab showed different results from that with using the traditional RECIST method. |